Rational Vaccines Inc.

Rational Vaccines Inc. is a corporate for-profit entity that develops novel vaccines and diagnostics related to infectious diseases, particularly herpes simplex virus (HSV) infections. Based in Massachusetts, the company has been actively engaged in several research initiatives funded by the National Institutes of Health (NIH) since 2022.

Through multiple Project Grants awarded by the NIH's National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), Rational Vaccines Inc. has received over $1.4 million in funding. A $576,176 award supports the development of an immunomodulatory vaccine (RVX1001) for preventing and treating HSV infections, with the goal of submitting an Investigational New Drug (IND) application to the FDA. Another $539,232 grant funds research on a novel prophylactic and therapeutic vaccine (VC2) for ocular HSV-1 infections, involving vaccination studies in rabbits. Additionally, a $291,480 grant enables the development of a highly specific and sensitive multiplex assay for detecting antibodies against HSV-2 in human sera, addressing an unmet clinical need for accurate type-specific HSV diagnostics. These projects leverage Rational Vaccines Inc.'s expertise in vaccine development and diagnostic technologies, contributing to innovative solutions for combating the global burden of herpes simplex virus infections.